Raymond James Financial
TARS icon

Raymond James Financial’s Tarsus Pharmaceuticals TARS Stock Holding History

Raymond James Financial’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.44M Sell
34,784
-865
-2% -$60.4K ﹤0.01% 3192
2025
Q4 		$2.92M Sell
35,649
-13,690
-28% -$1.02M ﹤0.01% 2950
2025
Q3 		$2.93M Buy
49,339
+4,624
+10% +$228K ﹤0.01% 2880
2025
Q2 		$1.81M Buy
44,715
+24,348
+120% +$1.1M ﹤0.01% 3157
2025
Q1 		$1.05M Buy
20,367
+368
+2% +$18.2K ﹤0.01% 3456
2024
Q4 		$1.11M Buy
+19,999
New +$908K ﹤0.01% 3383

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James Financial's TARS Position: Q1 2026 in Review

Raymond James Financial reduced its Tarsus Pharmaceuticals (TARS) stake by 2.4% in Q1 2026, selling an estimated $60.4K and leaving 34,784 shares worth $2.44M. The position accounts for ﹤0.01% of the portfolio, ranked #3192.

Raymond James Financial first reported a position in TARS in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.93M in Q3 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Raymond James Financial held 34,784 shares of Tarsus Pharmaceuticals worth $2.44M as of Q1 2026.
  • Raymond James Financial sold 865 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $60.4K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3192 holding.
  • Raymond James Financial first reported a position in Tarsus Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Tarsus Pharmaceuticals position peaked at $2.93M in Q3 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.